Lupus nephritis is diagnosed by either the presence of proteinuria (>0.5 g/day), active urinary sediment (with red blood cell, granular, tubular and/or mixed casts), or an unexplained rise in serum creatinine in patients with systemic lupus.

The diagnosis of SLE will be according to the 1997 American college of Romatology revised criteria (Hochberg 1997).these group will be taken as a control group

a group of age and sex matched healthy individuals will be taken as a control group.

Lupus Nephritis

Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as :
RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken.

Doppler ultrasonography of renal arteries

Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.

Renal biopsy

blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .

kidney function tests

The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .

The 24-hour urine protein test

A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.

complete blood counting (CBC)

Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis

Measurement of Renal Artery Resistive Index as a Predictor of Severity of Lupus Nephritis and Its Response to Treatment

the sum of RRI values in each group divided by the number of individuals in each group

Renal Resistive Index will be measured as :RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity .chronicity index score in renal biopsy will be calculated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. Result of renal biopsy will be reported within one weak.Correlation between RRI and chronicity index using correlation tests using SPSS version 20; pearson correlation test if the data are normally distributed and spearman correlation test if the data aren't normally distributed

pathological RRI(RRI>0.7) .Renal biopsy will be evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. There are 6 classes of lupus nephritis in renal biopsy. Number of patients in each class will be identified. the sum of RRI values in each class divided by the number of patients in each class

measurement of RRI in each patient with lupus nephritis . Blood sample from the same patient to measure blood urea nitrogen (BUN), serum creatinine(S Cr) and estimated glomerular filtration rate (eGFR) (using CKD-EPI Equation)

RRI will be measured for every patient with lupus nephritis at the beginning of the study. the patients will be followed for 6 months .BUN,S Cr , eGFR and and 24 h urinary protein excretion will be measured at the beginning of the study and every month for sex months to determine degree of response to treatment in patients with pathological RRI(0.7) compared to those with normal RRI.

RRI will be measured for every patient of lupus nephritis at the beginning of the study.Hemoglobin level will be measured at the beginning of the study and every month for sex months and the mean will be calculated

Yasser Abd Elmawgood Fysal Ibrahim

assistant lecturer

Assiut University

Gemcitabine doses: 300 mg/m2/week for 6 weeks.

Cervical Cancer

Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.
Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.
Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy.

Gemcitabine

National Institute of Cancer

Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease

A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease

Safety of gemcitabine regarding renal function will be assessed through glomerular filtration rate.
An improvement of 10 ml/min/1.73m2 as compared to basal glomerular rate is expected by the end of treatment.

Toxicity will be evaluated according to the toxicity criteria of CTCEA v. 4.03. A toxicity index of <4 is expected during treatment.

Dr. Lucely Cetina Pérez

MD, Master of Science

National Institute of Cancerología

Instituto Nacional de Cardiologia Ignacio Chavez

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase II open, single arm, national, non-randomized clinical trial; to evaluate safety of gemcitabine in patients with locally advanced cervical cancer and renal dysfunction, referring to the INCAN.

Subjects randomized to receive placebo (saline) sham saline injections on Days 0 and 90.

Subjects randomized to receive 100 units BOTOX-A injections on Days 0 and 90.

Subjects randomized to this group will receive placebo.

ARM 1

Subjects randomized to receive 100 units of BOTOX-A injections on Days 0 and 90.

ARM 2

Total

Sex: Female, Male

Region of Enrollment

This outcome measure was not able to be determined due to the subject being lost to follow-up. The subject no longer returns phone calls or visits the clinic.

Subjects randomized to receive 100 units of BOTOX-A on Days 0 and 90

A Change in DLPP of 20cm H2O at Day 30 and Day 120 in the BTX-A Injected Group (Group 1) Compared to the Sham Saline Injected Group (Group 2).

Patients in ARM 2 randomized to receive placebo (saline) injections on Days 0 and 90.

Patients in ARM 1 randomized to receive 100 units of BOTOX-A on Day 0 and Day 90

Overall Study

Christopher P. Smith, MD, MBA, MSS

Receiving placebo (saline injections)
Saline injection: Group 2-sham saline injections on both Day 0 and Day 90.

Receiving BOTOX-A
BOTOX-A: Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90

Neurogenic Bladder Dysfunction Nos

Spinal Cord Injury

Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90

BOTOX-A

Group 2-sham saline injections on both Day 0 and Day 90.

Saline injection

Baylor College of Medicine Clinical Research Studies

hydronephrosis/albumina

Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis

Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

O mais completo banco de dados de ervas medicinais apoiado pela ciência